Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility
Rhea-AI Summary
Tevogen Bio (TVGN) has signed an agreement with CD 8 Technology Services for developing a turn-key facility supporting in-house pre-clinical research and GMP cell therapy production capabilities. The agreement has an initial 12-month term with automatic renewal.
The facility will be primarily staffed and operated by Tevogen Bio, marking a strategic move to accelerate development timelines, maintain operational agility, and control costs. The company expects this agreement to help overcome typical capital barriers in building GMP capabilities at scale.
The agreement formalizes a previously announced letter of intent with CD8, a company associated with Dr. Manmohan Patel, who owns over 5% of Tevogen's common stock. Specific details including scope of work, costs, and timelines will be outlined in future work orders.
Positive
- Agreement enables in-house production capabilities without significant upfront capital investment
- Strategic move to accelerate development timelines and control costs
- Expansion of infrastructure for advancing CD8+ T cell therapeutics pipeline
Negative
- Related party transaction with 5% stakeholder raises potential conflict of interest concerns
- Specific costs and timeline details not yet determined
- Additional capital may be needed to execute business plan
News Market Reaction
On the day this news was published, TVGNW gained 5.23%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- The agreement would facilitate providing Tevogen Bio with in-house cell therapy production capabilities
- Formalized agreement aligns with previously announced topline forecasts
WARREN, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced it has entered into an agreement with CD 8 Technology Services LLC (“CD8”) for the development and/or acquisition of a turn-key facility that is intended to support both in-house pre-clinical research and GMP cell therapy production capabilities.
Tevogen Bio will provide the primary staff and operations for the facility, which is a key component of the company’s long-term strategy to accelerate development timelines, maintain operational agility, and control cost. Tevogen Bio believes that this agreement should allow the Company to overcome significant capital barriers of entry that are typically faced in building GMP capabilities at scale. The agreement has an initial term of 12 months and will automatically renew and aligns with the previously announced topline forecasts.
“This milestone represents a significant step forward in Tevogen Bio’s infrastructure expansion to support the advancement of its pipeline of off-the-shelf, genetically unmodified CD8+ T cell therapeutics,” commented Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio. “In addition, as we continue executing our mission to help patients, we’re also exploring additional ways to recognize our real, long-term shareholders.”
CD8 is associated with Dr. Manmohan Patel, who beneficially owns more than
Forward Looking Statements
This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; Tevogen’s ability to build GMP capabilities at scale; the prospective benefits of the agreement with CD8; expectations regarding future product revenues; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.
Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.
You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
FAQ
What is the purpose of Tevogen Bio's new facility agreement with CD8?
How long is the initial term of TVGNW's agreement with CD8 Technology Services?
Who will operate the new Tevogen Bio production facility?
What is the relationship between CD8 Technology Services and Tevogen Bio?
